Merck, a pharmaceutical company, completed the acquisition of Harpoon Therapeutics, a biotech company, for $680m. “At Harpoon, we have always been committed to advancing our cancer immunotherapy candidates to improve the lives of patients. With Merck’s recognized leadership in oncology clinical development and global commercial footprint, our lead candidate, HPN328, is well positioned moving forward,” Julie Eastland, Harpoon Therapeutics President and CEO.